BIOGEN INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of -$187.00 thousand for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-10-21.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2015-10-21
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-09-30 was -$187.00K, a 161.92% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-06-30 was $454.00K, a 74.62% increase year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2015-03-31 was $412.00K, a 55.47% increase year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-12-31 was -$47.00K, a 1040.00% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was $260.00K, a 78.10% decline from fiscal 2013.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2013 was $1.19M, a 75.04% decline from fiscal 2012.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2012 was $4.76M, a 3.23% decline from fiscal 2011.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2011 was $4.92M, a 409.85% increase from fiscal 2010.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month as first filed | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month |
|---|---|---|---|---|---|
| 2015-09-30 | -$187.00K 10-Q · filed 2015-10-21 | $267.00K derived: sum of 2 quarters · filed 2015-10-21 | -$229.00K 10-Q · filed 2015-10-21 | $632.00K derived: sum of 4 quarters · filed 2015-10-21 | |
| 2015-06-30 | $454.00K 10-Q · filed 2015-07-24 | $42.00K 10-Q · filed 2015-07-24 | $819.00K derived: sum of 3 quarters · filed 2015-07-24 | $1.12M derived: sum of 4 quarters · filed 2015-10-21 | |
| 2015-03-31 | $412.00K 10-Q · filed 2015-04-24 | $365.00K derived: sum of 2 quarters · filed 2015-04-24 | $667.00K derived: sum of 3 quarters · filed 2015-10-21 | $927.00K derived: sum of 4 quarters · filed 2015-10-21 | |
| 2014-12-31 | -$47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $255.00K derived: sum of 2 quarters · filed 2015-10-21 | $515.00K derived: sum of 3 quarters · filed 2015-10-21 | $260.00K 10-K · filed 2015-02-04 | |
| 2014-09-30 | $302.00K 10-Q · filed 2015-10-21 | $562.00K derived: sum of 2 quarters · filed 2015-10-21 | $307.00K 10-Q · filed 2015-10-21 | $832.00K derived: sum of 4 quarters · filed 2015-10-21 | |
| 2014-06-30 | $260.00K 10-Q · filed 2015-07-24 | $5.00K 10-Q · filed 2015-07-24 | $530.00K derived: sum of 3 quarters · filed 2015-07-24 | $232.00K derived: sum of 4 quarters · filed 2015-07-24 | |
| 2014-03-31 | $265.00K 10-Q · filed 2015-04-24 | $270.00K derived: sum of 2 quarters · filed 2015-04-24 | -$28.00K derived: sum of 3 quarters · filed 2015-04-24 | $31.00K derived: sum of 4 quarters · filed 2015-04-24 | |
| 2013-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | -$293.00K derived: sum of 2 quarters · filed 2015-02-04 | -$234.00K derived: sum of 3 quarters · filed 2015-02-04 | $1.19M 10-K · filed 2015-02-04 | |
| 2013-09-30 | -$298.00K 10-Q · filed 2014-10-22 | $298.00K 10-Q · filed 2013-10-28 | -$239.00K derived: sum of 2 quarters · filed 2014-10-22 | $1.18M 10-Q · filed 2014-10-22 | $2.82M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-06-30 | $59.00K 10-Q · filed 2014-07-23 | $1.48M 10-Q · filed 2014-07-23 | $3.12M derived: sum of 3 quarters · filed 2015-02-04 | $6.26M derived: sum of 4 quarters · filed 2015-02-04 | |
| 2013-03-31 | $1.42M 10-Q · filed 2014-04-23 | $3.06M derived: sum of 2 quarters · filed 2015-02-04 | $6.20M derived: sum of 3 quarters · filed 2015-02-04 | $8.36M derived: sum of 4 quarters · filed 2015-02-04 | |
| 2012-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $4.78M derived: sum of 2 quarters · filed 2015-02-04 | $6.94M derived: sum of 3 quarters · filed 2015-02-04 | $4.76M 10-K · filed 2015-02-04 | |
| 2012-09-30 | $3.14M 10-Q · filed 2013-10-28 | $5.30M derived: sum of 2 quarters · filed 2013-10-28 | $3.12M 10-Q · filed 2013-10-28 | $9.73M derived: sum of 4 quarters · filed 2014-02-06 | |
| 2012-06-30 | $2.16M 10-Q · filed 2013-07-25 | $22.00K 10-Q · filed 2013-07-25 | $6.59M derived: sum of 3 quarters · filed 2014-02-06 | $10.44M derived: sum of 4 quarters · filed 2014-02-06 | |
| 2012-03-31 | $2.14M 10-Q · filed 2013-04-25 | $4.42M derived: sum of 2 quarters · filed 2014-02-06 | $8.27M derived: sum of 3 quarters · filed 2014-02-06 | $9.09M derived: sum of 4 quarters · filed 2014-02-06 | |
| 2011-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $6.13M derived: sum of 2 quarters · filed 2014-02-06 | $6.95M derived: sum of 3 quarters · filed 2014-02-06 | $4.92M 10-K · filed 2014-02-06 | |
| 2011-09-30 | $3.85M 10-Q · filed 2012-10-25 | $4.67M derived: sum of 2 quarters · filed 2012-10-25 | $2.63M 10-Q · filed 2012-10-25 | ||
| 2011-06-30 | $822.00K 10-Q · filed 2012-07-24 | $1.21M 10-Q · filed 2012-07-24 | |||
| 2010-12-31 | $964.00K 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |